The Senate Committee on Armed Services will hear testimony Tuesday (April 30) on Department of Defense (DOD) initiatives to ensure pharmaceutical safety, in a hearing that is likely to touch on issues of generic drug quality and American dependence on pharmaceuticals manufactured in China. The committee’s subcommittee on personnel will hear testimony on DOD’s “efforts to ensure servicemembers’ access to safe, high-quality pharmaceuticals.” DOD’s pharmaceutical efforts were spotlighted by a report from Bloomberg in December that FDA intervened to...